EIF4G1 and neoplasm: Additionally, YAP inhibitor (Verteporfin [Ver], 2.5 μm) and eIF4F inhibitors (4EGI‐1, 2.5 μm and SAN, 2 μm) significantly reduced the size and YAP expression of Apcmin/+EcsitcKO tumor organoids (Figure 5H,I and Figure S16E,F, Supporting Information) illustrating for the role of the eIF4F‐YAP axis in driving the pro‐tumorigenic phenotype resulting from ECSIT deficiency.